VACCINES: India’s Strength

  • View

  • Download

Embed Size (px)



Text of VACCINES: India’s Strength


2. Safe Harbour Statement

  • These materials are not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the Securities Act).The shares of Intercell AG (the Company) have not been and will not be registered under the Securities Act and will be offered and sold in the United States only to qualified institutional buyers in reliance on Rule 144A and outside the United States in reliance on Regulation S.You should not base your decision to invest in the Companys shares on these materials.Any decision to invest in the Companys shares should be based solely on the information contained in the offering document (the Offering Document) that will be prepared in connection with the offer and sale of the Companys shares referred to herein (the Offering).The Offering will be made only to qualifying investors by means of the Offering Document.These materials are strictly confidential and must not be disclosed or distributed to third parties.
  • During the course of this presentation, the Company may make projections or other forward-looking statements regarding, among other things, the progress, timing and completion of our research, development and clinical trials for product candidates, the Companys ability to market, commercialize and achieve market acceptance for product candidates, its ability to protect its intellectual property and operate its business without infringing on the intellectual property rights of others, the Companys estimates for future performance and its estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing.In addition, even if the Companys actual results or development are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of the companys results or developments in the future. In some cases, you can identify these forward looking statements by words such as could, may, expects, anticipates, believes, intends, estimates, or similar words.These forward-looking statements are based largely on the Companys current expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties and other factors that may cause its actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized.Except as otherwise required by applicable securities laws, we disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
  • These materials are directed only at persons (I) who are outside the United Kingdom or (II) who have professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the Order) or (III) who fall within article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order (all such persons together being referred to as Relevant Persons).Any person who is not a Relevant Person must not act or rely on this communication or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

FEBRUARY 3, 2009 BIO ASIA 2009 PAGE 3. Agenda FEBRUARY 3, 2009 BIO ASIA 2009 PAGE

    • Infection and Prophylaxis
    • Intercell in a Nutshell
    • Japanese Encephalitis
    • Vaccination in India
    • A European Indian Partnership

4. Microbial infections key threat to human life FEBRUARY 3, 2009 BIO ASIA 2009 PAGE

    • Terminate of every 4 th human life
    • Three major killers: Malaria, AIDS and Tuberculosis
    • Multi-drug resistant microbes
    • Novel emerging pathogens
    • Bioterrorism
    • Pandemic influenza

OVERVIEW Worldwide approx. 500,000people killed by the annual flu epidemic Estimated50,000,000people killed by pandemic flu1918

    • 13 million deaths per year in developing countries

Egon Schiele, 1890 - 1918 5. Infectious diseases:a continuous threat for the developed and less developed world FEBRUARY 3, 2009 BIO ASIA 2009 PAGEEXAMPLES INFECTIOUS DISEASES >300m people infected1.5m deaths per year Malaria 2bn people latently infected 3m deaths per year Tuberculosis 40m people infected >15m deaths so far AIDS i.e. Germany: >40,000 deaths per year, ~10% of all deaths in hospitals Hospitalinfections 170m people infected >50,000 deaths per year Hepatitis C 6. Drastic decrease of HIB Meningitis after introduction of new vaccine in US FEBRUARY 3, 2009 BIO ASIA 2009 PAGEVaccine doses in m Cases per 100,000 VACCINES WORK 7. Agenda FEBRUARY 3, 2009 BIO ASIA 2009 PAGE

    • Infection and Prophylaxis
    • Intercell in a Nutshell
    • Japanese Encephalitis
    • Vaccination in India
    • A European Indian Partnership

8. FEBRUARY 3, 2009 BIO ASIA 2009 PAGEPeople: Key Management : G. Zettlmeissl (CEO), A. v. Gabain (CSO and co-founder),T. Lingelbach (COO) & W. Lanthaler (CFO) Supervisory board : M. Grco, E.G. Afting,S. Bakali,D. Ebsworth, J. Sulat, H. WigzellSAB :R. Ahmed, H. Blum, S. Cohen, F.X. Heinz, S. Kaufmann, S. Normark, H. Wigzell Celebrating 10 years continuous success INTERCELL IN A NUTSHELL History: Spin off from the Campus Vienna Biocenter, IMP and University 1998 Today ca. 350 employees from 16 nations in Vienna, Austria, Livingston UK and Gaithersburg, USA Partners: Novartis, Merck (USA), Sanofi Aventis, Wyeth, Kirin, SSI, Biological E, EC, NIH, CDC, WRAIR, AERAS foundation, Karolinska, MPI, GBF and many academic organizationsProducts:Therapeutic & prophylactic vaccines and antibody treatments based oncutting edge R&D Funding:3 private VC rounds , since 2005 listed at the ATX (ICLL): todays Market cap: ca. $ 1.5 Bill 9. Vaccine innovation FEBRUARY 3, 2009 BIO ASIA 2009 PAGEOUR VALUE PROPOSITION IC31 New vaccine adjuvants AIP Technology generating novel vaccine and antibody productsVaccine patch Technology for vaccine delivery with patch

  • New global travelers' vaccines
    • Japanese Encephalitisvaccine expected market approval US/EU/AUS 2008, India 2009 Market potential: EUR 250m 350m
    • Travelers' Diarrheavaccine patch expected start of Phase III early 2009 Market potential: > EUR 0.5bn
  • Hospital-acquired infections (vaccines & antibodies)
    • Leading approach for vaccines & antibodies
      • S. aureusvaccine in Phase II Market potential: > EUR 3bn
      • Pseudomonasvaccine expected start of Phase II/IIIin 2008 Market potential: > EUR 1bn

* Strategic PartnershipsProducts Technologies

  • Leading products for
    • Therapeutic Hepatitis Cvaccine in Phase II
    • Patch / Pandemic Fluvaccine in Phase I/II
    • IC31 / Seasonal Fluvaccine in Phase I/II
    • Protein-basedPneumococcusvaccine expected start of Phase I in 2009
    • IC31 / TBvaccine in Phase I/II
    • Market potential: > EUR 0.5-3bnpertarget

Innovative biotech company for vaccines, antibodies and delivery technology 10. Significant areas of unmet medical need FEBRUARY 3, 2009 BIO ASIA 2009 PAGE

    • Cholera
    • Diphtheria
    • H. influenza B
    • Hepatitis A
    • Hepatitis B
    • Influenza
    • Japanese Encephalitis
    • Measles
    • Meningitis C
    • Mumps
    • Papilloma
    • Pertussis
    • Pneumococcus
    • Polio
    • Rota
    • Rubella
    • Tetanus
    • Tick Borne Encephalitis
    • Typhus
    • Varicella


    • Borrelia
    • Candida
    • Chlamydia
    • Cytomegalovirus